Lieping Chen

17PUBLICATIONS
57CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Innate immunityMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Aug 07, 2026
Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial.

|Apr 26, 2024
Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity.

Tianxiang Zhang, Weiwei Yu, Xiaoxiao Cheng

|Dec 28, 2022
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary.

Ignacio Melero, Miguel F Sanmamed, Javier Glez-Vaz

|Jun 14, 2022
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.

Tae Kon Kim, Esten N Vandsemb, Roy S Herbst

|May 26, 2022
The CD8α-PILRα interaction maintains CD8+ T cell quiescence.

Linghua Zheng, Xue Han, Sheng Yao

|Jul 29, 2021
Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy.

Yi Sun, Wei Chen, Robert J Torphy

Pageof 3

Frequent Collaborators

3 joint publications

Xue Han

3 joint publications

Matthew D. Vesely

2 joint publications

Weiwei Yu

2 joint publications

Jun Wang